Pyrazolo [4,3-e][1,2,4]triazolo[1,5-c]pyrimidine template:: Organic and medicinal chemistry approach

被引:16
作者
Baraldi, PG
Tabrizi, MA
Romagnoli, R
El-Kashef, H
Preti, D
Bovero, A
Fruttarolo, F
Gordaliza, M
Borea, PA
机构
[1] Univ Ferrara, Dipartimento Sci Farmaceut, I-44100 Ferrara, Italy
[2] Assiut Univ, Fac Sci, Dept Chem, Assiut 71516, Egypt
[3] Univ Salamanca, Dept Quim Farmaceut, Salamanca 37007, Spain
[4] Univ Ferrara, Dipartimento Med Clin & Sperimentale, Sez Farmacol, I-44100 Ferrara, Italy
关键词
D O I
10.2174/138527206775473869
中图分类号
O62 [有机化学];
学科分类号
070303 ; 081704 ;
摘要
Here we report our medicinal chemistry approach on the synthesis of the pyrazolo[4,3-e][1,2,4]triazolo[1,5c]pyrimidines and related compounds that have permitted us to complete the SAR analyses on this class of chemical molecules. Evaluating their pharmacological profiles, we planned several structural modifications to modulate the biological activity versus the different adenosine receptor subtypes. Efforts made by our research group led to the discovery of a variety of selective antagonists for the A(2A) and A(3) receptors, performing modifications at the N-7, N-8, N-5, C-9, C-2-position of the pyrazolo-triazolo-pyrimidine core and by the replacement of the 2-(2-furyl)[1,2,4]triazole molecular part with substituted 2-thioxotriazole, dioxotriazine, oxotriazine, and 1,2,4-triazepine moieties. Modifications at the N-7(-) pyrazole performed by the introduction of different alkyl or arylalkyl chains, led us to the discovery of very potent and selective A(2A) receptor antagonists, whereas, functionalisations at the N-5-position together with the modulation of the pattern of substitution on the N-8-pyrazole nitrogen revealed new A3 antagonists (40, 41) suitable to represent candidate for the pharmacological and clinical investigations. Other modifications performed to the tricyclic nucleus, such as the introduction at the C-9-position of thioethyl, aminoalkyl and (cyclo)alkylamino radicals (compounds 50-66) and the replacement of the 2-furyl moiety with substituted aromatic rings (compounds 48 a-f and 49a, b) led to a diminished receptor affinity. Also the replacement of the 2-(2-furyl)triazolo template with new heterocycles revealed inactive molecules but allowed us to real understand what structural modifications introduced on the pyrazolo-triazolo-pyrimidine structure played am important role on ligand-receptor interaction. In this way, we notice what position of the heterocyclic structure is not allowed to be modified and, on the contrary, what position is susceptible of modifications or functionalizations.
引用
收藏
页码:259 / 275
页数:17
相关论文
共 44 条
[1]   Synthesis of new pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines and related heterocycles [J].
Baraldi, PG ;
El-Kashef, H ;
Farghaly, AR ;
Vanelle, P ;
Fruttarolo, F .
TETRAHEDRON, 2004, 60 (23) :5093-5104
[2]   Recent developments in the field of A3 adenosine receptor antagonists [J].
Baraldi, PG ;
Tabrizi, MA ;
Fruttarolo, F ;
Bovero, A ;
Avitabile, B ;
Preti, D ;
Romagnoli, R ;
Merighi, S ;
Gessi, S ;
Varani, K ;
Borea, PA .
DRUG DEVELOPMENT RESEARCH, 2003, 58 (04) :315-329
[3]   Recent developments in the field of A2A and A3 adenosine receptor antagonists [J].
Baraldi, PG ;
Tabrizi, MA ;
Bovero, A ;
Avitabile, B ;
Preti, D ;
Fruttarolo, F ;
Romagnoli, R ;
Varani, K ;
Borea, PA .
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2003, 38 (04) :367-382
[4]   Design, synthesis, and biological evaluation of C9- and C2-substituted pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c] pyrimidines as new A2A and A3 adenosine receptors antagonists [J].
Baraldi, PG ;
Fruttarolo, F ;
Tabrizi, MA ;
Preti, D ;
Romagnoli, R ;
El-Kashef, H ;
Moorman, A ;
Varani, K ;
Gessi, S ;
Merighi, S ;
Borea, PA .
JOURNAL OF MEDICINAL CHEMISTRY, 2003, 46 (07) :1229-1241
[5]   New strategies for the synthesis of A3 adenosine receptor antagonists [J].
Baraldi, PG ;
Bovero, A ;
Fruttarolo, F ;
Romagnoli, R ;
Tabrizi, MA ;
Preti, D ;
Varani, K ;
Borea, PA ;
Moorman, AR .
BIOORGANIC & MEDICINAL CHEMISTRY, 2003, 11 (19) :4161-4169
[6]   Synthesis and preliminary biological evaluation of [3H]-MRE 3008-F20:: the first high affinity radioligand antagonist for the human A3 adenosine receptors [J].
Baraldi, PG ;
Cacciari, B ;
Romagnoli, R ;
Varani, K ;
Merighi, S ;
Gessi, S ;
Borea, PA ;
Leung, E ;
Hickey, SL ;
Spalluto, G .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2000, 10 (03) :209-211
[7]  
Baraldi PG, 1996, J LABELLED COMPD RAD, V38, P725, DOI 10.1002/(SICI)1099-1344(199608)38:8<725::AID-JLCR885>3.0.CO
[8]  
2-G
[9]   Pyrazolo-triazolo-pyrimidine derivatives as adenosine receptor antagonists: A possible template for adenosine receptor subtypes? [J].
Baraldi, PG ;
Cacciari, B ;
Borea, PA ;
Varani, K ;
Pastorin, G ;
Da Ros, T ;
Tabrizi, MA ;
Fruttarolo, F ;
Spalluto, G .
CURRENT PHARMACEUTICAL DESIGN, 2002, 8 (26) :2299-2332
[10]   7-substituted 5-amino-2-(2-furyl)pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as A2A adenosine receptor antagonists:: A study on the importance of modifications at the side chain on the activity and solubility [J].
Baraldi, PG ;
Cacciari, B ;
Romagnoli, R ;
Spalluto, G ;
Monopoli, A ;
Ongini, E ;
Varani, K ;
Borea, PA .
JOURNAL OF MEDICINAL CHEMISTRY, 2002, 45 (01) :115-126